Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

4-Hydroxy-oxyphenbutazone is a potent inhibitor of cytokine production.

Authors:
Anja Ten Brinke David W C Dekkers Silla M Notten Miriam L Karsten Els R de Groot Lucien A Aarden

Eur Cytokine Netw 2005 Jun;16(2):144-51

Department of Immunopathology, Sanquin Research at CLB, PO.BOX 9190, 1006 AD Amsterdam, The Netherlands.

4-Hydroxy-oxyphenbutazone (4OH-OPB), is currently in phase II trials for its immunosuppressive effect in patients with rheumatoid arthritis. 4OH-OPB and other compounds related to phenylbutazone were tested for their effect on in vitro cytokine production by monocytes and lymphocytes present in peripheral mononuclear cells (PBMC) or whole blood (WB) cultures, and compared against phenylbutazone and oxyphenbutazone, two known anti-inflammatory drugs. In PBMC cultures, 4OH-OPB was by far the most potent inhibitor, and both monokines and Th1 and Th2 lymphokines were efficiently inhibited at low concentrations. In WB cultures, 4OH-OPB was less effective than in PBMC cultures, but was still the best inhibitor of lymphokine production and, furthermore, was the only inhibitor of monokine production. The increase in 4OH-OPB concentration needed to induce the same inhibition of cytokine production in WB as in PBMC culture could be mimicked by the addition of erythrocytes to the PBMC cultures. Experiments with radioactively-labeled 4OH-OPB suggest that 4OH-OPB is taken up very rapidly into erythrocytes and is secreted by the erythrocytes with much slower kinetics via a multidrug-resistance-associated protein. The secreted compound is most likely structurally different from 4OH-OPB, as in PBMC and WB cultures, the inhibition of cytokine production seems to be caused by a different mechanism. In PBMC cultures, the inhibition of cytokine production is accompanied by a loss of cell viability, while this is not the case when 4OH-OPB inhibits cytokine production in WB. Our data suggest that 4OH-OPB may be useful as an immunosuppressive drug for patients with inflammatory diseases.

Download full-text PDF

Source
June 2005

Publication Analysis

Top Keywords

cytokine production
24
pbmc cultures
20
inhibition cytokine
12
4oh-opb
10
cultures inhibition
8
potent inhibitor
8
production
8
cultures 4oh-opb
8
cultures
7
pbmc
7
cytokine
6
concentration needed
4
needed induce
4
induce inhibition
4
inflammatory diseases
4
production pbmc
4
pbmc culture
4
4oh-opb concentration
4
mimicked addition
4
addition erythrocytes
4

Keyword Occurance

Similar Publications

A adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models.

Authors:
Apple Hui Min Tay Rubén Prieto-Díaz Shiyong Neo Le Tong Xinsong Chen Valentina Carannante Björn Önfelt Johan Hartman Felix Haglund Maria Majellaro Jhonny Azuaje Xerardo Garcia-Mera Jose M Brea Maria I Loza Willem Jespers Hugo Gutierrez-de-Teran Eddy Sotelo Andreas Lundqvist

J Immunother Cancer 2022 May;10(5)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Background: Adenosine is a metabolite that suppresses antitumor immune response of T and NK cells via extracellular binding to the two subtypes of adenosine-2 receptors, AARs. While blockade of the AARs subtype effectively rescues lymphocyte activity, with four AAR antagonists currently in anticancer clinical trials, less is known for the therapeutic potential of the other AAR blockade within cancer immunotherapy. Recent studies suggest the formation of AAR/AAR dimers in tissues that coexpress the two receptor subtypes, where the AAR plays a dominant role, suggesting it as a promising target for cancer immunotherapy. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Investigating the multi-target therapeutic mechanism of Guihuang formula on Chronic Prostatitis.

Authors:
Shengjing Liu Feng Zhao Yingjun Deng Yin Zeng Bin Yan Jun Guo Qinghe Gao

J Ethnopharmacol 2022 May 14:115386. Epub 2022 May 14.

Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China. Electronic address:

Ethnopharmacological Relevance: Chronic prostatitis (CP) is a complex, intractable and prevalent urological disorder in men with no effective treatment. Guihuang formula (GHF) is a traditional Chinese medicine compound that is advantageous as a CP treatment, but its aetiology is poorly understood. Research and exploration of the mechanism of GHF will help the development of a potentially valuable drug for CP and provide deeper insight into CP. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Synthesis of Novel Immunomodulatory 1,4-Disubstituted Bis-1,2,3-triazoles by Using Click Chemistry and Their Intracellular Mechanism of Action.

Authors:
Yahya Nural Irem Acar Derya Yetkin Cagla Efeoglu Zeynel Seferoglu Furkan Ayaz

Bioorg Med Chem Lett 2022 May 14:128800. Epub 2022 May 14.

Department of Biotechnology, Faculty of Arts and Science, Mersin University, TR-33440, Mersin, Turkey; Mersin University Biotechnology Research and Application Center, Mersin University, TR-33440, Mersin, Turkey.

In this study, six new 1,4-disubstituted bis-1,2,3-triazole compounds, N,N'-(1,2-phenylene)bis(2-(4-R-1H-1,2,3-triazol-1-yl)acetamide), were synthesized with high yield (88-96%) by using click chemistry and their molecular structures were characterized by using NMR, FT-IR, HRMS and elemental analysis techniques. Previous studies suggest anti-inflammatory and analgesic activities for different 1,2,3-triazole derivatives and in the light of those studies we aimed to examine these novel derivatives immunomodulatory activities on the mammalian macrophages. Pro-inflammatory cytokines (TNF, IL6, GMCSF and IL12p40) secretion levels were tested in the presence of bis-1,2,3-triazole compounds when the macrophages were activated with LPS. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.

Authors:
Juanfeng Lao Can Cao Xiaoli Niu Simei Deng Siqi Ming Siping Liang Yuqi Shang Yulin Yuan Xiaomin Shi Zibin Liang Minhao Wu Yongjian Wu

Int Immunopharmacol 2022 May 14;108:108813. Epub 2022 May 14.

Guangdong Provincial Engineering Research Center of Molecular Imaging, Guangdong Provincial Key Laboratory of Biomedical Imaging, and Department of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China; Lead Contact. Electronic address:

Immune-checkpoint blockade is widely studied for cancer therapy. Although the co-inhibitory receptor Programmed death-1(PD-1) blockade benefits some non-small cell lung cancer (NSCLC) patients, a large portion of NSCLC patients still fail to respond to this immunotherapy, and the underlying mechanism is unclear. Thus, a synergistic therapy to enhance the effect of PD-1 is urgently needed to improve the poor outcome of NSCLC patients. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Porphyromonas gingivalis outer membrane vesicles modulate cytokine and chemokine production by gingipain-dependent mechanisms in human macrophages.

Authors:
Y Castillo J E Castellanos G I Lafaurie D M Castillo

Arch Oral Biol 2022 May 12;140:105453. Epub 2022 May 12.

Unidad de Investigación Básica Oral (UIBO), Vicerrectoría de investigaciones, Facultad de Odontología, Universidad El Bosque, Bogotá, Colombia. Electronic address:

Objective: The aim was to determine the changes of inflammatory mediator expression in human macrophages stimulated with outer membrane vesicles purified from Porphyromonas gingivalis.

Design: outer membrane vesicles purified by ultracentrifugation from ATCC 33277 and W83 P. gingivalis strains were used for stimulating human macrophages and determine their inflammatory mediator expression changes. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap